Literature DB >> 8543500

The pharmacokinetics of meropenem in infants and children: a population analysis.

E M Parker1, M Hutchison, J L Blumer.   

Abstract

Plasma meropenem concentration versus time data collected during a single dose, pharmacokinetic study in infants and children were analysed using the population pharmacokinetics program NONMEM. A total of 300 meropenem concentrations was obtained from 65 patients ranging from 2 months to 12 years of age; weighing between 3.7 and 46 kg. A two-compartment open pharmacokinetic model with a zero-order infusion over 30 min was fitted to the data. The most important determinant of meropenem clearance was the creatinine clearance but an additional improvement occurred when a nonlinear dependence upon age was included. The most important determinant of the volume of distribution in the central and peripheral compartments was the body weight. The distributional clearance showed a nonlinear dependence on body weight. Demographic factors other than weight and age were not found to be influential in the model. Both clearance and distributional clearance were markedly different in the younger (< 2 years) or lighter (< 10 kg) patients, respectively. Thereafter the parameter values slowly approached those found in adults. In this study, a mean of 4.6 samples per patient was used to provide information on the pharmacokinetics and the determinants of the pharmacokinetic variability in infants and children. The findings in the younger, lighter patients, if generally applicable, might have significance for the dosage recommendations for drugs with narrow therapeutic indices.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8543500     DOI: 10.1093/jac/36.suppl_a.63

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients.

Authors:  Piergiorgio Cojutti; Natalia Maximova; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

2.  Meropenem in neonatal severe infections due to multiresistant gram-negative bacteria.

Authors:  N Köksal; M Hacimustafaoğlu; S Bağci; S Celebi
Journal:  Indian J Pediatr       Date:  2001-01       Impact factor: 1.967

3.  Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.

Authors:  Partha Nandy; Mahesh N Samtani; Rachel Lin
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

4.  Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children.

Authors:  Jeffrey J Cies; Wayne S Moore; Adela Enache; Arun Chopra
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jul-Aug

Review 5.  Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.

Authors:  David Aguilera-Alonso; Luis Escosa-García; Jesús Saavedra-Lozano; Emilia Cercenado; Fernando Baquero-Artigao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

6.  Population pharmacokinetics of amphotericin B in children with malignant diseases.

Authors:  C E Nath; A J McLachlan; P J Shaw; R Gunning; J W Earl
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

Review 7.  Bayesian forecasting in paediatric populations.

Authors:  M M Fernández de Gatta; M J García; J M Lanao; A Domínguez-Gil
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

Review 8.  Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.

Authors:  E Samara; R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

9.  Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Pediatric Patients.

Authors:  Jumpei Saito; Kensuke Shoji; Yusuke Oho; Hiroki Kato; Shotaro Matsumoto; Satoshi Aoki; Hidefumi Nakamura; Takanori Ogawa; Mayumi Hasegawa; Akimasa Yamatani; Isao Miyairi
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

Review 10.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.